Atossa Therapeutics, Inc. Overview
Pro stress-test →Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on transforming breast cancer treatment through its lead candidate, (Z)-endoxifen, a highly potent selective estrogen receptor modulator. The company is addressing significant unmet medical needs across multiple breast cancer settings, with a strategic focus on metastatic breast cancer as its lead indication.
Strategic Profile
Pro stress-test →Atossa has pivoted from its origins in breast health diagnostics to become a focused oncology biotech company centered on a single high-potential asset. The company benefits from a strong balance sheet ($65.1M cash, no debt as of Q1 2025) and positive FDA feedback that cleared the path to file an IND for (Z)-endoxifen in metastatic breast cancer, positioning it for potential expedited regulatory pathways.
Competitive Landscape
Pro stress-test →Atossa competes in the breast cancer therapeutics space against major pharmaceutical companies and other biotech firms developing endocrine therapies and targeted oncology treatments. Key competitors include established hormone therapy developers and emerging immunotherapy/CAR-T platforms, though Atossa's focus on (Z)-endoxifen's differentiated potency and profile may provide competitive advantage in specific patient populations.
Industry Context
Atossa Therapeutics, Inc. operates in Oncology Biopharmaceuticals.
Key facts
Founded: 2009 · Headquarters: Seattle, United States · Revenue: $0M